This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Powerful perspectives
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All articles
Press release
€80 million Series B financing to progress pipeline through Phase II trials
Data & publication
Roginolisib: an oral, highly selective and allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3kδ) in patients with uveal melanoma and advanced cancers
Press release
US FDA grants orphan drug designation for iOnctura’s first-in-class autotaxin cancer therapy
Data & publication
The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
Data & publication
Safety and clinical efficacy of IOA-289, a novel autotaxin inhibitor, plus gemcitabine and nabpaclitaxel (GnP) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)
Data & publication
Preclinical activity of novel TGF beta receptor I kinase Inhibitors IOA-359 and IOA-360 for treatment of anemia in MDS/AML
Data & publication
Novel PI3Kδ inhibitor roginolisib synergizes with the Bcl-2 inhibitor venetoclax in hematological malignancies
Press release
Updated clinical safety and efficacy data for iOnctura’s roginolisib presented at ESMO immuno-oncology congress 2023
Data & publication
Safety and clinical efficacy of roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase Inhibitor delta (PI3Kδ)
Press coverage
pharmaphorum — Uveal melanoma: a new generation of therapies offers hope for patients
Press coverage
Immuno-Oncology Insights — Navigating the complexities of immunotherapy: unraveling novel targets & pathways
Press coverage
Drug Target Review — Combining autotaxin and TGF-β inhibitors in cancer
Looking for media
resources?